Comparative Pharmacology
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus ZAVESCA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELIGLUSTAT TARTRATE versus ZAVESCA.
ELIGLUSTAT TARTRATE vs ZAVESCA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eliglustat is a glucosylceramide synthase inhibitor that reduces the biosynthesis of glucocerebroside, a glycolipid that accumulates in Gaucher disease. It acts as a substrate reduction therapy by decreasing the rate of production of glucocerebroside to a level that allows the residual enzyme activity to clear accumulated substrate.
Inhibits glucosylceramide synthase, reducing synthesis of glycosphingolipids including glucocerebroside.
100 mg orally three times daily, at regular intervals (every 8 hours).
100 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is 6.1 to 8.4 hours. In patients with hepatic impairment (Child-Pugh class B or C), half-life may be prolonged (up to 14-22 hours), requiring dose adjustment.
6-7 hours; in patients with hepatic impairment, up to 12-15 hours.
Renal: 41.4% (unchanged drug and metabolites); fecal: 55.4% (mostly as metabolites). Approximately 2% of the dose is excreted unchanged in urine.
Renal (predominantly): 70% unchanged, fecal: 20% as metabolites, biliary: minor.
Category C
Category C
Glucosylceramide Synthase Inhibitor
Glucosylceramide Synthase Inhibitor